- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 71
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Chronic Kidney Disease, IgA Nephropathy
- Interventions
- Bortezomib (Velcade®)
- Drug
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- Felzartamab, Placebo
- Drug · Other
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more
- Conditions
- IgA Nephropathy
- Interventions
- AVB-S6-500
- Drug
- Lead sponsor
- Aravive, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Doral, Florida
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Low inflammation diet intervention
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Manhattan Beach, California
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- BION-1301, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
- Conditions
- IgA Nephropathy
- Interventions
- Placebo, LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- CCX168
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Francisco, California • Reno, Nevada + 2 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Chula Vista, California • Garden Grove, California + 21 more
- Conditions
- IgA Nephropathy, Proteinuria
- Interventions
- Acthar 80 unit injection
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- IgA Nephropathy
- Interventions
- JADE101
- Drug
- Lead sponsor
- Jade Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Chula Vista, California • Arvada, Colorado • Denver, Colorado + 3 more
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy
- Interventions
- Ravulizumab, Placebo, Background Therapy
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- San Dimas, California • Santa Monica, California • South Gate, California + 13 more
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Interventions
- Atacicept 150 mg
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- IgA Nephropathy
- Interventions
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Drug · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 5
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- IgA Nephropathy
- Interventions
- TARPEYO®
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more
- Conditions
- Progressive IgA Nephropathy, Proteinuria
- Interventions
- ACTH (Acthar) Gel
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more
- Conditions
- IGA Nephropathy
- Interventions
- Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Augusta, Georgia • Columbus, Ohio + 1 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- No intervention, Other treatment, Iptacopan, Atrasentan
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Interventions
- Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
- Conditions
- Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 6 more
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- zigakibart
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Acworth, Georgia • Edina, Minnesota
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Interventions
- ADX-097
- Drug
- Lead sponsor
- Q32 Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
- Conditions
- Glomerular Disease
- Interventions
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Dietary Supplement
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more